Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Endothelial cell–specific LAT1 ablation normalizes tumor vasculature
Jun-ichi Suehiro, Toru Kimura, Toshiyuki Fukutomi, Hisamichi Naito, Yasuharu Kanki, Youichiro Wada, Yoshiaki Kubota, Nobuyuki Takakura, Hiroyuki Sakurai
Jun-ichi Suehiro, Toru Kimura, Toshiyuki Fukutomi, Hisamichi Naito, Yasuharu Kanki, Youichiro Wada, Yoshiaki Kubota, Nobuyuki Takakura, Hiroyuki Sakurai
View: Text | PDF
Research Article Angiogenesis Vascular biology

Endothelial cell–specific LAT1 ablation normalizes tumor vasculature

  • Text
  • PDF
Abstract

Some endothelial cells in the tumor vasculature express a system L amino acid transporter, LAT1. To elucidate the role of LAT1 in tumor-related endothelial cells, tumor cells were injected into endothelial cell–specific LAT1 conditional knockout mice (Slc7a5flox/flox; Cdh5-Cre-ERT2), and we found that the shape of the tumor vasculature was normalized and the size and numbers of lung metastasis was reduced. TNF-α–induced expression of VCAM1 and E-selectin at the surface of HUVEC, both of which are responsible for enhanced monocyte attachment and premetastatic niche formation, was reduced in the presence of LAT1 inhibitor, nanvuranlat. Deprivation of tryptophan, a LAT1 substrate, mimicked LAT1 inhibition, which led to activation of MEK1/2-ERK1/2 pathway and subsequent cystathionine γ lyase (CTH) induction. Increased production of hydrogen sulfide (H2S) by CTH was at least partially responsible for tumor vascular normalization, leading to decreased leakiness and enhanced delivery of chemotherapeutic agents to the tumor.

Authors

Jun-ichi Suehiro, Toru Kimura, Toshiyuki Fukutomi, Hisamichi Naito, Yasuharu Kanki, Youichiro Wada, Yoshiaki Kubota, Nobuyuki Takakura, Hiroyuki Sakurai

×

Figure 2

LAT1 inhibition led to a decrease in intracellular tryptophan levels, resulting in suppression of TNF-α–mediated VCAM1 expression and monocyte adhesion via MEK1/2-ERK1/2 signaling cascade.

Options: View larger image (or click on image) Download as PowerPoint
LAT1 inhibition led to a decrease in intracellular tryptophan levels, re...
(A) qPCR analysis of VCAM1, E-selectin, and ICAM1 mRNA expression in 10 ng/mL TNF-α–stimulated HUVEC with 100 μM captisol or nanvuranlat. (B) Western blot analysis of VCAM1 expression in TNF-α–stimulated HUVEC with 100 μM Captisol or nanvuranlat. β-actin was used as a loading control. Blots provided together were set up in parallel at the same time. (C) qPCR analysis of TNF-α–mediated VCAM1 mRNA expression treated with indicated signal transduction inhibitors. The inhibitor name and concentration were LY, 50 μM LY294002: Ra, 1 μM rapamycin; SB, 20 μM SB203580; SP, 50 μM SP600125; PD9, 50 μM PD98059; PD0, 50 μM PD0325901; and H89,20 μM H-89. (D) Western blot analysis of phosphorylation of indicated proteins in TNF-α–stimulated HUVEC for 10 minutes with 100 μM Captisol, 100 μM nanvuranlat, or 1 μg/mL rapamycin. Blots provided together were set up in parallel at the same time. (E) Measurement of intracellular amino acid concentration by LC-MS/MS analysis in 100 μM Captisol (vehicle control) or nanvuranlat treated HUVEC. Graph showed mean ± SEM (n = 4) of intracellular amino acid concentration in vehicle control (blue circle) or nanvuranlat (red square) condition. (F) U937 monocyte adhesion to HUVEC in the presence of Captisol, nanvuranlat, and/or PD0325901. Graph showed mean ± SD (n = 6). (G) U937 monocyte adhesion to HUVEC in the tryptophan or leucine deprivation media. Graph showed mean ± SD (n = 4). (H) qPCR analysis of VCAM1 mRNA expression in HUVEC cultured in tryptophan-starved MCDB131 media. (A) P values were determined by 2-tailed, unpaired t test. (E) P values were determined by 1-way ANOVA with Tukey’s multiple comparisons test compared to control at 0.5 hour. (C and F–H) P values were determined by 1-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05. Scale bars: 200 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts